The Global Tissue Sealants Market is expected to grow at a high CAGR of 9.22% during the forecasting period (2023-2030).
Tissue sealants are increasingly essential elements in modern medicine, with rapid development over the past 30 years. They enable the natural wound healing processes to occur through the adhesion of tissue to the tissue on-site or tissue to non-tissue surfaces on-site, thus exhibiting some attractive characteristics in the clinic, such as less traumatic closure and suffering, easy application, no stitches required after surgery, excellent cosmetic result, and localized drug release. Moreover, these tissue sealants are extensively used in different tissues, including breast, skin, head & neck, cardiac, gastrointestinal, hepatic, neurological, pediatric, orthopedic, thoracic, dental, bone and vascular surgery. The tissue sealants offer various significant features such as lower infection rate, reduced operating time, good cosmetic result, no risk of needle-stick injury, lower cost, no need for post-operative structure removal, and immediate wound sealing and ease to use.
Metrics |
Details |
Market CAGR |
9.22% |
Segments Covered |
By Application, By Type, and By Region |
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
Fastest Growing Region |
Asia Pacific |
Largest Market Share |
North America |
For more details on this report Request for Sample
Fibrin sealants are expected to drive market growth due to the high demand and utilization of hemostats for surgeries. Hemostats, or clamps, are devices used in surgical procedures to control bleeding. They are widely employed in complex processes, such as during cardiac surgeries, where most care needs to be taken. The demand for these devices is further grown due to increased heart surgeries. According to analysis, a total of 12,175 adult cardiac surgeons and 3855 pediatric cardiac surgeons were listed in the cardiothoracic surgery network in August 2017.
Furthermore, the growing demand for tissue sealants in various applications such as neurological, otolaryngology, colorectal, pulmonary, cardiovascular surgeries is expected to boost the tissue sealants market during the forecast period. Moreover, biological tissue sealants are expected to hold the largest market share during the forecast period due to cost-effectiveness, prevent leakages, and enable shorter procedure duration. In addition, the biological tissue sealants market is classified into fibrin tissue sealants, collagen-based natural tissue sealants, albumin tissue sealants and many more. Due to the wide range of classification, biological tissue sealants are the key driver for market growth. Further, synthetic tissue sealants are classified into polyethylene glycol tissue sealants and cyanoacrylate-based tissue sealants. The primary function of synthetic tissue sealants is to stop bleeding.
By type, the market is segmented into natural/biological, synthetic & semisynthetic and biomimetic. By application, the market is segmented into surgical suture materials, hemostatic glue, wound dressings, soft tissue, neurosurgical, orthopedic, cardiac surgeries and others.
The most basic fibrin sealants consist of two components: thrombin with a small amount of calcium chloride and fibrinogen, enabling the adhesive to mimic hemostasis's final stages. Moreover, it has the most extended history and the broadest range of applications, including cardiovascular surgery, neurosurgery, plastic surgery, and spleen and liver lacerations.
However, fibrin-based sealants show a mechanical strength reduction under wet conditions (e.g., in the presence of a significant amount of blood), and this makes them unsuitable for supporting tissue joints with substantial tensile loads to be applied on wet substrates. Therefore, they are combined with sutures or staples or used with a carrier sponge to counter brisk bleeding during surgery. Moreover, the risk of disease transmission is a significant issue in fibrin-based sealants since it is derived from human or animal plasma, even when heat inactivation and solvent/detergent extraction methods are used to reduce viral risk contamination. To avoid the problem of possible contamination, virus-inactivated fibrin sealants were developed. These adhesives offer excellent biocompatibility and low toxicity, while they have a complex preparation procedure, slow curing, and relatively poor bonding strength.
North America holds the largest market share for tissue sealants due to advancements in the healthcare infrastructure, government policies, and the growing population of patients. The U.S. dominates the tissue sealant market due to an increase in the number of bone injuries and sports injuries and a rise in the number of hip and knee replacement surgeries, which have led to the fast growth of the global tissue sealants market. According to the U.S. Department of Health and Human Services, in the U.S., about 29 million children and teens participate in some form of organized sports, and it is estimated around 8.5 million sports injuries occur each year.
APAC is expected to contribute significant growth for the tissue sealant market during the forecast period due to the presence of untapped medical needs of this region's patient population and improve healthcare infrastructure in India and China's emerging economies, which is expected to drive the market growth.
The tissue sealants market is fragmented with the presence of regional and global players. The competitive contour lies with the increase in the regional company and growing investment in upstream application. Johnson & Johnson Services Inc., Baxter, Integra LifeSciences Corporation, C.R. Bard Inc., Cohesion Technologies, Inc., Avin Darou, Adhesys Medical GmbH, Dickinson & Company, Cohera Medical Inc., Becton are the major player in the sealants market. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to growing the tissue sealants market globally.
Baxter
Baxter manufacture TISSEEL, which helps surgeons address bleeding in sites inaccessible to "surgical" means (i.e., sutures and cautery) with uniform placement thanks to DUPLOSPRAY System, allowing surgeons to get as close as 2-5 cm to the tissue for laparoscopic surgery. Moreover, as a leader in hemostasis, the company is committed to providing innovative solutions for surgeons. TISSEEL is effective across surgical specialties and is for adjunctive hemostasis across a wide range of surgical specialties to:
The company also provide some indications such as:
Hemostasis: TISSEEL is a fibrin sealant indicated for use as an adjunct to hemostasis in adult and pediatric patients (>1 month of age) undergoing surgery when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. TISSEEL is effective in heparinized patients.
Sealing: TISSEEL is a fibrin sealant indicated as an adjunct to standard surgical techniques (such as suture and ligature) to prevent leakage from colonic anastomoses following the reversal of temporary colostomies.
Visualize the composition of the Tissue Sealants Market across each indication, regarding type and application highlighting the critical commercial assets and players.
Identify business opportunities in Tissue Sealants Market by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of the Tissue Sealants Market levels 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for the essential Tissue Sealants Market of all major market players.
Raw Material Suppliers/ Buyers
Product Suppliers/ Buyers
Industry Investors/Investment Bankers
Education & Research Institutes
Research Professionals
Emerging Companies
Manufacturers
$4350
$4350
$4350
$4350
$4350
$4350